A Phase III Randomized Study Comparing a Chemotherapy with Cisplatin and Etoposide to a Etoposide Regimen without Cisplatin for Patients with Extensive Small-Cell Lung Cancer
IntroductionIn a literature meta-analysis, we showed survival benefits for regimens including cisplatin [hazard ratio (HR) 0.61; 95% confidence interval (CI), 0.57–0.66] and for those including etoposide (HR 0.65; 0.61–0.69). That benefit was mainly observed when etoposide alone or in combination wi...
Main Authors: | Thierry Berghmans, Arnaud Scherpereel, Anne-Pascale Meert, Vicente Giner, Jacques Lecomte, Jean-Jacques Lafitte, Nathalie Leclercq, Marianne Paesmans, Jean-Paul Sculier, for the European Lung Cancer Working Party (ELCWP) |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-09-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fonc.2017.00217/full |
Similar Items
-
Advances in target therapy in lung cancer
by: Jean-Paul Sculier, et al.
Published: (2015-03-01) -
Updates in oncology
by: Jean-Paul Sculier, et al.
Published: (2014-03-01) -
Continuous renal replacement therapy for acute renal failure in patients with cancer: a well-tolerated adjunct treatment
by: Rebecca Fischler, et al.
Published: (2016-08-01) -
Are intensive cares worthwhile for breast cancer patients: the experience of an oncological ICU.
by: Virginie Destrebecq, et al.
Published: (2016-10-01) -
VAC chemotherapy with valproic acid for refractory/relapsing small cell lung cancer: a phase II study
by: Thierry Berghmans, et al.
Published: (2015-10-01)